Trial Profile

A Prospective, Open Label, Safety and Efficacy Study of Infusions of HepaStem in Urea Cycle Disorders Pediatric Patients

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mesenchymal stem cell therapy (Primary)
Indications Inborn urea cycle disorders
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms HEP002KR
Sponsors HLB LifeScience; LifeLiver

Most Recent Events

04 Nov 2020 Planned End Date changed from 1 Dec 2020 to 4 Nov 2020.
04 Nov 2020 Planned primary completion date changed from 1 Dec 2020 to 4 Nov 2020.
04 Nov 2020 Status changed from recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com